Comment on “An Injectable Hydrogel to Modulate T Cells for Cancer Immunotherapy”

Abstract Recent clinical successes of immune checkpoint blockade (ICB) therapies represents a milestone as a novel anti‐tumor strategy beyond surgery, radiotherapy, chemotherapy, and targeted therapy in cancer therapy. T cells, especially CD8⁺ T cells, play crucial roles in anti‐tumor immune responses. However, most T cells in the tumor microenvironment express high inhibitory receptors, such as PD‐1, TIM‐3, and LAG‐3, and decreased T cell response in response to stimuli. Applying ICB therapies, such as anti‐PD‐1, promotes T cell activation and increases cytotoxic T lymphocyte (CTL) response, leading to the enhanced anti‐tumor immune response in patients with malignancy. Therefore, studies aimed to define novel targets that can restrain T cell terminal exhaustion are urgently required to provide new strategies for patients resistant to immunotherapy. The previously published study by Zhang et al. (An Injectable Hydrogel to Modulate T Cells for Cancer Immunotherapy, https://doi.org/10.1002/smll.202202663) introduces a new type of injectable hydrogel that can regulate the function of T cells, thereby improving their effectiveness in cancer immunotherapy. However, it remains to be discussed for its conclusion, as the flow cell assay of this article may not be proper.